Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Non-Clinical Biodistribution & Targeting Evaluation Services for In Vivo CAR

Online Inquiry

Background Service What We Can Offer Workflow Specialty Services Highlights FAQs Published Data Contact

Creative Biolabs delivers preclinical biodistribution and target localization assessment solutions for in vivo CAR constructs, aiding the advancement of cell therapies with enhanced safety and predictable in vivo behavior. This suite of services resolves core developmental bottlenecks, including ambiguous tissue distribution patterns, insufficient data on in vivo target-binding potency, risks of unintended off-target gene transfer, and obstacles to measuring how long CAR-engineered vectors persist and are cleared from biological systems.

Introduction

As in vivo CAR technologies continue to advance, biodistribution and targeting assessments have become essential components of preclinical development. Published studies have demonstrated that therapeutic constructs can exhibit dynamic distribution patterns across blood, lymphoid organs, target tissues, and non-target organs following administration. Recent scientific literature highlights the importance of evaluating tissue exposure, persistence, clearance kinetics, and target engagement using molecular, imaging, and histological approaches. These findings support the use of comprehensive biodistribution and targeting studies to improve candidate selection, optimize delivery strategies, and enhance overall development confidence.

Our Service

Successful in vivo CAR development requires a clear understanding of where therapeutic constructs distribute, how efficiently target cells are modified, and whether non-target tissues are exposed. Creative Biolabs provides comprehensive non-clinical evaluation solutions designed to generate actionable data supporting candidate selection, safety assessment, and translational development.

Our services enable clients to characterize whole-body biodistribution after administration, evaluate tissue targeting efficiency and target cell binding, analyze cell persistence, clearance and dynamic distribution, detect off-target exposure and non-specific transduction, compare different delivery approaches and doses, and produce complete data sets to support preclinical research and regulatory filings.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Analysis of Non-Clinical Biodistribution & Targeting Evaluation for In Vivo CAR. (Creative Biolabs Original)

We conduct full biodistribution analysis covering organs and lesion sites, measuring targeting efficiency, cell persistence, clearance and off-target distribution alongside tumor homing and multi-organ safety. Our toolkit combines longitudinal optical/nuclear imaging, and flow cytometry, multiplex staining for histological and cellular assessment.

Our Workflow

To start our biodistribution and targeting evaluation, clients shall supply CAR construct and delivery system details, test therapeutic preparations, plus target background, animal models, administration plans and study goals.

Workflow of Non-Clinical Biodistribution & Targeting Evaluation for In Vivo CAR. (Creative Biolabs Original)

You will receive full biodistribution reports, organ quantitative data, targeting and persistence analyses, imaging visuals, histological results, plus statistical data and research conclusions.

Specialty Services

Multi-Organ Vector Distribution & Off-Target Profiling for In Vivo CAR

Employing ultra-sensitive tracking, this service maps systemic vector distribution across vital organs. It systematically identifies off-target delivery and unintended gene expression, providing critical specificity data to ensure patient safety and meet strict regulatory standards.

Learn More →

Germline Transmission & Sensitive Tissue Testing (DRG) for In Vivo CAR

To eliminate reproductive and neurological risks, our platform performs rigorous molecular assays detecting vector leakage into germlines and dorsal root ganglia. This specialized screening guarantees definitive safety profiling, safeguarding your therapeutic design before clinical translation.

Learn More →

Benefits

Non-clinical biodistribution and targeting evaluation solutions for diverse in vivo CAR development programs, from early candidate screening to advanced preclinical studies.
Customized study design based on therapeutic modality, target biology, delivery strategy, administration route, and project-specific development objectives.
Multi-organ biodistribution assessment across blood, lymphoid tissues, major organs, target tissues, and disease-relevant sites to support exposure characterization.
Molecular analysis platforms including quantitative nucleic acid detection, transgene persistence assessment, vector copy determination, and longitudinal tissue distribution profiling.

FAQs

Q: What information can biodistribution studies provide for in vivo CAR programs?

A: These studies provide insights into tissue distribution, targeting efficiency, persistence, clearance behavior, and potential off-target exposure. Such information can support candidate selection and development planning.

Q: Which tissues are commonly analyzed?

A: Depending on project objectives, analyses may include blood, liver, spleen, lung, kidney, lymphoid tissues, bone marrow, target tissues, and additional organs of interest.

Q: What methods are available for tracking distribution in vivo?

A: A combination of molecular quantification, imaging technologies, cellular analysis, and tissue-based evaluations can be utilized to generate complementary datasets.

Q: How are off-target distribution risks assessed?

A: Off-target assessment typically involves evaluating non-target tissues using quantitative molecular assays, tissue localization analyses, and histological examination to identify unintended exposure patterns.

Published Data

This study uses non-invasive zirconium isotope imaging to observe different doses of lymphoma-targeted CAR-T cells in tumor-bearing mice, without harming cells. Cells stay in lungs for hours then move to liver and spleen for days. Medium and high doses gather more in tumors. Verified by separate tissue tests, this imaging method tracks cell distribution to guide treatment.

Fig.1 Maging analysis for CAR-T cells in vivo. (OA Literature) Fig.1 Quantitative image evaluation of in vivo CAR-T cells.¹

Partner with Us

Creative Biolabs provides comprehensive Non-Clinical Biodistribution & Targeting Evaluation Services for In Vivo CAR programs, supporting the characterization of tissue distribution, targeting efficiency, persistence, clearance, and off-target exposure. Through integrated molecular, imaging, cellular, and histological evaluation platforms, we help researchers generate robust datasets for informed development decisions. For detailed information regarding our Non-Clinical Biodistribution & Targeting Evaluation Services for In Vivo CAR, please contact our scientific team.

Reference

Sta Maria, Naomi S et al. "Spatio-temporal biodistribution of 89Zr-oxine labeled huLym-1-A-BB3z-CAR T-cells by PET imaging in a preclinical tumor model." Scientific reports vol. 11,1 15077. 23 Jul. 2021. Distributed under Open Access LicenseCC BY 4.0, without modification. https://doi.org/10.1038/s41598-021-94490-0

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.